Laden…
cis-(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
Tramadol is a synthetic opioid with analgesic effects, acting both as a μ-opioid receptor agonist and as a reuptake inhibitor of serotonin and norepinephrine. It is used for the treatment of moderate to moderately severe pain. Due to its mechanisms of action, there is a risk of dependence, serotonin syndrome, and other side effects. The combination with other serotonergic substances should be avoided.
Class
Opioide
Pharmacological context
Mechanism
Tramadol ist ein atypisches Opioid mit dualem mechanism of action. (1)...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: cis-(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
Frequently checked combinations
Effects & Pharmacology is partially translated. Some details are still being expanded.
Tramadol ist ein atypisches Opioid mit dualem mechanism of action. (1) Schwacher direkter μ-Opioid-Agonist (Ki ~2µM). Der aktive Metabolit O-Desmethyltramadol (via CYP2D6-Metabolisierung) ist ein potenter μ-Opioid-Agonist (Ki ~3nM, ~200× potenter als Tramadol). (2) SERT- und NET-Reuptake-Inhibitor (serotoninerge und noradrenerge Aktivität). Das duale Wirkprinzip macht Tramadol einzigartig unter Opioiden und erklärt sowohl die analgetische Wirkung als auch das erhebliche Serotonin-Syndrom-Risiko. Das CYP2D6-Polymorphismus bestimmt maßgeblich die Umwandlungsrate zum aktiven Metaboliten – langsame Metabolisierer haben schwächere Effekte, schnelle Metabolisierer höhere Toxizität.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 100–200 mg
Total duration 6–8 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 50 mg |
| Reported | 100–200 mg |
| Strong | 300 mg+ |
Oral
Onset
30–60 minutes
Peak
1–2 hours
Total duration
6–8 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Evidence
strong
Safer Use
Depressant-risk context
This substance belongs to a context where combinations with opioids, benzodiazepines, alcohol, GHB/GBL, or other sedating substances can increase sedation, blackout, aspiration, and breathing-risk patterns. Risk Check can review warning patterns; it is not medical advice and it cannot clear a combination as safe.
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.